Navigation Links
Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
Date:9/20/2007

pment of new drugs to treat various forms of cancer and gastrointestinal diseases. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including gastrointestinal disorders. One of the Company's lead drug candidates, Atiprimod is presently in a Phase II clinical trial in advanced carcinoid cancer patients, a neuroendocrine tumor, and in a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory acute leukemia, a currently incurable blood cancer. L-Annamycin is currently in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Callisto also has a proprietary drug Guanilib in preclinical development for gastro- intestinal disorders. Callisto has exclusive worldwide licenses from Genzyme Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. More information is available at http://www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty i
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... , Oct. 22, 2014  Quest Diagnostics (NYSE: ... information services, today announced that its Board of Directors ... a director, effective December 1, 2014. Including Dr. Leiden, ... is the Chairman, President and CEO of Vertex Pharmaceuticals. ... scientific and commercial experience in the pharmaceutical and biotechnology ...
(Date:10/22/2014)... Calif. , Oct 22, 2014 Antigen ... Irvine, California , announced the receipt of ... Business Innovation Research award (SBIR) from the National Institute of Dental ... fund the development of a Pan-HIV Protein Microarray Chip, ... HIV-1 and HIV-2 subtypes and aid in the development ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... Oct. 13 The Care Continuum Alliance ... Award for the "Greatest Impact on Health" at ...  The ALL/PHASE protocol, which utilizes low-cost and generic medications ... successfully implemented in Kaiser Permanente communities, including those served ...
... Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna -- OOSTERHOUT, Netherlands, Oct. 13 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 4Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 5Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 6Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 7Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 8Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 9
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the ... in the field of establishing recovery community organizations. Bob ... when he retired, he set out to answer a couple ... , 1. Where are the people in recovery ... 2. Can the recovery community be organized to advocate for ...
(Date:10/25/2014)... The Wehrman Collaborative, LLC ... for disabled users by disabled users, has granted ... Mackin Educational Resources of Burnsville, Minnesota, for their ... to the Minnesota Alliance for Patient Safety of ... website. Both organizations have met WeCo’s ...
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for ... prices. Bob Seger & The Silver Bullet Band tickets ... are going on sale October 25 and are expected ... browse the selection of tickets for Bob Seger & ... singer is touring North America beginning next month, and ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
(Date:10/25/2014)... Limbkeepers® announced today that they will be featured ... Jr, airing 1st QTR 2015 via Discovery Channel. Dates ... will focus on Limbkeepers® non compression knit sleeves, a ... arms, hands, and legs from abrasion, skin tears and ... help reduce injuries, allow for continued daily activities, and ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2
... It was a "common sense" decision to start the ... of the stroke belt. , "We wanted to give better ... of the Department of Neurology at the Medical College of ... 2000 and Hess and his colleagues were frustrated that nearly ...
... Researchers at UT Southwestern Medical Center have developed what ... new imaging technique to diagnose brain tumors. The unique test ... are located in areas of the brain too dangerous to ... a definitive diagnosis of cancer based on imaging of a ...
... , THURSDAY, Jan. 26 (HealthDay News) -- Popular cholesterol-lowering statins may ... a new study shows. Hepatitis B, an inflammation of the liver ... causes of liver cancer. This is not the first ... Other studies have hinted that these drugs may play a role ...
... (HealthDay News) -- Positive reinforcement, such as receiving small, ... seems to help patients with high blood pressure take ... of black Americans. The findings are significant because ... and death, the researchers from the Center for Healthful ...
... lung clearance index (LCI) is a sensitive non-invasive marker of ... according to a new study from Australian researchers. "We ... especially in the presence of airway inflammation and Pseudomonas aeruginosa," ... the Sydney Children,s Hospital. "LCI may not only be a ...
... Reporter , THURSDAY, Jan. 26 (HealthDay News) -- The rate ... dramatic upturn since 2004, reversing a trend of decline throughout ... place outside of the traditional hospital setting increased 29 percent ... to 0.72 percent -- almost 30,000 births -- according to ...
Cached Medicine News:Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Diagnostic brain tumor test could revolutionize care of patients 2Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Positive Reinforcement May Help Patients Take Their Meds 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2Health News:More U.S. Babies Born at Home: Report 2Health News:More U.S. Babies Born at Home: Report 3
... The Aisys Carestation helps you deliver unmatched ... Aisys Carestation is the most complete anesthesia ... point of need - at your fingertips., ... our industry-leading Datex-Ohmeda legacy of anesthesia delivery ...
... Mesh LP is a super-light polypropylene mesh ... body reaction is reduced considerably. Optilene Mesh ... all open hernia repair procedures. It perfectly ... flexibility Optilene Mesh LP adapts to the ...
... Optilene Mesh Elastic is a lightweight and ... elasticity the mesh is able to adapt to ... The new honeycomb like structure with the large ... elastic scar. The mesh is ideal for incisional ...
... LP is a lightweight polypropylene mesh ... considerably reduced,foreign body reaction. The softer, ... It perfectly conforms to,anatomical structures. Due ... LP adapts to the movements of ...
Medicine Products: